Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, 2-period, crossover study to establish the dose equivalence and direct conversion between immediate release (IR) and extended-release (ER) CG5503 [tapentadol] in subjects with moderate-to-severe, chronic low back pain.

Next Previous
X
Search
Trial Profile

A randomized, double-blind, 2-period, crossover study to establish the dose equivalence and direct conversion between immediate release (IR) and extended-release (ER) CG5503 [tapentadol] in subjects with moderate-to-severe, chronic low back pain.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tapentadol (Primary) ; Tapentadol (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 05 Feb 2010 According to a media release from Johnson & Johnson, results will be presented at the American Academy of Pain Medicine's 26th annual meeting.
    • 29 Jan 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Planned number of patients changed from 75 to 120 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top